tradingkey.logo

Prenetics Global Ltd

PRE
18.380USD
+0.900+5.15%
收盘 12/22, 16:00美东报价延迟15分钟
236.99M总市值
亏损市盈率 TTM

Prenetics Global Ltd

18.380
+0.900+5.15%

关于 Prenetics Global Ltd 公司

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.

Prenetics Global Ltd简介

公司代码PRE
公司名称Prenetics Global Ltd
上市日期Jul 06, 2021
CEOKwok (Samantha)
员工数量285
证券类型Ordinary Share
年结日Jul 06
公司地址Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Hong Kong
邮编- -
电话85222109588
网址https://ir.prenetics.com/
公司代码PRE
上市日期Jul 06, 2021
CEOKwok (Samantha)

Prenetics Global Ltd公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
Ms. Jordan Lemerande
Ms. Jordan Lemerande
Vice President - Product Development
Vice President - Product Development
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Ms. Wing Kwan (Winnie) Chiu
Ms. Wing Kwan (Winnie) Chiu
Independent Director
Independent Director
--
--
Mr. Joel Neoh
Mr. Joel Neoh
Chief Consumer Officer, Chief Executive Officer of CircleDNA
Chief Consumer Officer, Chief Executive Officer of CircleDNA
--
--
Mr. Alan Thomas
Mr. Alan Thomas
Vice President, Supply Chain & Operations
Vice President, Supply Chain & Operations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
Ms. Jordan Lemerande
Ms. Jordan Lemerande
Vice President - Product Development
Vice President - Product Development
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
Hong Kong
14.27M
46.59%
Taiwan
7.09M
23.16%
The United States
5.51M
18.00%
United Kingdom
2.78M
9.08%
Rest of the world
972.00K
3.17%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月17日 周三
更新时间: 12月17日 周三
持股股东
股东类型
持股股东
持股股东
占比
Dennis (Lo Yuk Ming)
7.69%
Genetel Bioventures Ltd
4.90%
Lawrence (Tzang Chi Hung)
4.29%
Eastspring Investments (Singapore) Limited
3.42%
Aspex Management (HK) Limited
2.76%
其他
76.94%
持股股东
持股股东
占比
Dennis (Lo Yuk Ming)
7.69%
Genetel Bioventures Ltd
4.90%
Lawrence (Tzang Chi Hung)
4.29%
Eastspring Investments (Singapore) Limited
3.42%
Aspex Management (HK) Limited
2.76%
其他
76.94%
股东类型
持股股东
占比
Individual Investor
13.28%
Corporation
4.90%
Investment Advisor
3.77%
Hedge Fund
2.97%
Research Firm
2.63%
Investment Advisor/Hedge Fund
0.68%
Bank and Trust
0.35%
其他
71.43%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
23
1.16M
9.26%
-1.28M
2025Q2
30
3.73M
32.59%
-1.27M
2025Q1
31
3.72M
35.24%
-295.48K
2024Q4
35
3.71M
34.90%
-336.29K
2024Q3
37
3.69M
34.65%
-448.54K
2024Q2
38
3.76M
35.34%
-535.47K
2024Q1
88
5.56M
55.93%
+1.27M
2023Q4
94
4.17M
42.91%
+30.90K
2023Q3
99
4.01M
43.06%
+108.37K
2023Q2
98
3.11M
36.85%
-918.88K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Dennis (Lo Yuk Ming)
962.96K
8.41%
--
--
Apr 24, 2025
Genetel Bioventures Ltd
613.79K
5.36%
--
--
Sep 30, 2024
Lawrence (Tzang Chi Hung)
537.10K
4.69%
--
--
Apr 24, 2025
Eastspring Investments (Singapore) Limited
427.96K
3.74%
--
--
Jun 30, 2025
Aspex Management (HK) Limited
346.15K
3.02%
--
--
Jun 30, 2025
Nomura Securities Co., Ltd.
321.82K
2.81%
-11.70K
-3.51%
Jun 30, 2025
Chun (Lo Hoi)
162.62K
1.42%
--
--
Apr 24, 2025
UBS Switzerland AG
394.00
0%
-706.00
-64.18%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.03%
iShares Micro-Cap ETF
占比0.03%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
公告日期
类型
比率
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1

常见问题

Prenetics Global Ltd的前五大股东是谁?

Prenetics Global Ltd 的前五大股东如下:
Dennis (Lo Yuk Ming)持有股份:962.96K,占总股份比例:8.41%。
Genetel Bioventures Ltd持有股份:613.79K,占总股份比例:5.36%。
Lawrence (Tzang Chi Hung)持有股份:537.10K,占总股份比例:4.69%。
Eastspring Investments (Singapore) Limited持有股份:427.96K,占总股份比例:3.74%。
Aspex Management (HK) Limited持有股份:346.15K,占总股份比例:3.02%。

Prenetics Global Ltd的前三大股东类型是什么?

Prenetics Global Ltd 的前三大股东类型分别是:
Dennis (Lo Yuk Ming)
Genetel Bioventures Ltd
Lawrence (Tzang Chi Hung)

有多少机构持有Prenetics Global Ltd(PRE)的股份?

截至2025Q3,共有23家机构持有Prenetics Global Ltd的股份,合计持有的股份价值约为1.16M,占公司总股份的9.26%。与2025Q2相比,机构持股有所增加,增幅为-23.33%。

哪个业务部门对Prenetics Global Ltd的收入贡献最大?

在FY2024,--业务部门对Prenetics Global Ltd的收入贡献最大,创收--,占总收入的--%。
KeyAI